rvt-1401
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Apr 22, 2019 (NCT03922321)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- IgG receptor FcRn large subunit p51INHIBITOR
FCGRT inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04253236 | Phase 2 | Jan 29, 2020 | Immunovant Sciences GmbH |
| NCT03938545 | Phase 2 | Jun 30, 2019 | Immunovant Sciences GmbH |
| NCT03863080 | Phase 2 | May 21, 2019 | Immunovant Sciences GmbH |
| NCT03922321 | Phase 2 | Apr 22, 2019 | Immunovant Sciences GmbH |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immunovant Sciences GmbH | For profit | 4 | 4 | 1 | 2019 |
1 organizations
Page 1 / 1